Oxybiane Homocystéine Regul
Food supplement declared in France, decision dated 29 September 2025
Oxybiane Homocystéine Regul is a food supplement declared in France. Status: declared in France, may be marketed. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.
- Brand
- not provided
- Food business operator placing the product on the market
- PILEJE
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 1 gélule
- Directions for use
- 1 gélule par jour à avaler avec un verre d'eau. Durée de la complémentation : 1 mois
- Intended populations
- General population, Men and women aged 18 and over
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Pregnant women, Taking anticoagulants, Taking medication, Prolonged use
- Objectives stated by the manufacturer (these are not authorised claims)
- Antioxydant, Autre : métabolisme de l'homocystéine
Declaration 342508, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Curcuma longa L. | Rhizome | Extrait sec hydroalcoolique | 71 mg |
| Allium cepa L. | Bulbe | Extrait sec aqueux | 50 mg |
| Bambusa bambos (L.) Voss | Exsudat | Poudre (de plantes séchées ou broyées) | 5.1 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Acétylcystéine | not declared |
| Resvératrol | not declared |
| Hydrolysat enzymatique de protéines de riz | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| D-pantothénate de calcium | Acide pantothénique (vitamine B5) | pas de limite (données insuffisantes) | dose annulled by the French Council of State in 2011 |
| D-biotine | Biotine (vitamine B8) | pas de limite (données insuffisantes) | dose annulled by the French Council of State in 2011 |
| acide (6S)-5-méthyltétrahydrofolique sous forme de sel de glucosamine | Folates (vitamine B9) | 1,000 µg | 200 µg |
| Sulfate de manganèse | Manganèse | 8 mg (safe level) | 3.5 mg |
| Nicotinamide | Nicotinamide (vitamine B3) | 900 mg | 54 mg |
| Mononitrate de thiamine | Vitamine B1 (thiamine) | pas de limite (données insuffisantes) | dose annulled by the French Council of State in 2011 |
| Méthylcobalamine | Vitamine B12 | pas d'effet indésirable défini | dose annulled by the French Council of State in 2011 |
| Riboflavine | Vitamine B2 (riboflavine) | pas de limite (données insuffisantes) | dose annulled by the French Council of State in 2011 |
| Chlorhydrate de pyridoxine | Vitamine B6 | 12 mg | 2 mg |
| Citrate de zinc | Zinc | 25 mg | 15 mg |
Additives
E471, E570
Other ingredients
amidon de maïs, Gélule végétale
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Réservé à l’adulte. Déconseillé aux femmes enceintes et allaitantes. Déconseillé chez les personnes sous anticoagulants, anticancéreux, immunosuppresseurs et souffrant de pathologies des voies biliaires (obstruction biliaire ou troubles de la fonction biliaire). Usage prolongé déconseillé. Les personnes prenant des médicaments ne devraient consommer le produit que sous contrôle médical.
Regulatory points
None of the rules we check applies to the declared ingredients.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Curcuma longa L.
Read the warning, when it applies and the studies cited
TURMERIC - CURCUMA LONGA - Oral
Route of administration: Oral (ESCOP 2003; Blumenthal et al. 2000)
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (ESCOP 2003; Brinker 2001; McGuffin et al. 1997).
Sources cited by Health Canada (2)
- ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder (HC 2025; EMA 2018; Brinker 2010; ESCOP 2003; McGuffin et al. 1997).
Sources cited by Health Canada (6)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2018. European Medicines Agency. European Union herbal monograph on Curcuma longa L., rhizome. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 25 September 2018. [Accessed 2023 October 14] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-curcuma-longa-l-rhizoma-revision-1_en.pdf
- ESCOP: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking medications (HC 2025).
Sources cited by Health Canada (2)
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience any new symptoms including yellowing of the eyes or skin, dark urine, nausea, vomiting, stomach pain (HC 2025).
Sources cited by Health Canada (2)
- HC 2025: Health Canada: Summary Safety Review - Turmeric and Curcuminoids for Oral Use - Assessing the Potential Risk of Hepatotoxicity. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR1758121117867
- SC 2025: Santé Canada : Résumé de l'examen de l'innocuité - Curcuma et curcuminoïdes pour usage oral - Évaluation du risque potentiel d'hépatotoxicité. Disponible à : https://pmps.hpfb-dgpsa.ca/documents-d-examen/ressource/SSR1758121117867
Condition of application: All uses except for Source of antioxidants and Hepatoprotectant.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 26 September 2025
Turmeric -CURCUMA LONGA - Topical
Cautions and warnings
For external use only.
When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.
Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.
Contraindications
Do not use on deep or puncture wounds, animal bites or serious burns.
- Acétylcystéine
Read the warning, when it applies and the studies cited
N-ACETYL-L-CYSTEINE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney stones (Fauci et al. 1998; Mårtensson et al. 1990).
Sources cited by Health Canada (2)
- Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DI, Hauser SL and Longo DL, editors. Harrison's Principles of Internal Medicine, 14th edition. Toronto (ON): McGraw-Hill Health Professions Division; 1998.
- Mårtensson J, Denneberg T, Lindell Å, Textorius O. Sulfur amino acid metabolism in cystinuria : A biochemical and clinical study of patients. Kidney International 1990;37:143-149. PubMed
Contraindications
Do not use if you are taking antibiotics or nitroglycerin (Repchinsky 2008; Cederlund and Märdh 1993; Parry and Neu 1977; Ardissino et al. 1997).
Sources cited by Health Canada (4)
- Ardissino D, Merlini PA, Savonitto S, Demicheli G, Zanini P, Bertocchi F, Falcone C, Ghio S, Marinoni G, Montemartini C, Mussini A. Effect of transdermal nitroglycerin or N- acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. Journal of the American College of Cardiology 1997;29(5):941-947. PubMed Randomised trial
- Cederlund H, Märdh PA. Antibacterial activities of non-antibiotic drugs. Journal of Antimicrobial Chemotherapy 1993;32:355-365. PubMed Review article
- Parry MF, Neu HC. Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro. Journal of Clinical Microbiology 1977;5(1);58-61.
- Repchinsky C, editor. Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- Oxybiane Homocystéine Regul PILEJE, declared in 2026 : same declared composition
- Oxybiane Homocystéine Regul PILEJE, declared in 2023 : same declared composition
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.